Authors

Ronald D. Wiehle, Ph.D., Gregory Fontenot, Ph.D., Jenny Wike, B.S., Kuang Hsu, M.S., Jennifer Nydell, B.S. Larry Lipshultz, M.D.

Volume 102, Issue 3, Pages 720-727

Abstract

Objective:

To determine the effect of enclomiphene citrate in men with secondary hypogonadism.

Design:

Phase II clinical trial.

Setting:

Community dwelling men making visits to physician offices.

Patient(s):

Men with secondary hypogonadism.

Intervention(s):

Oral administration of enclomiphene citrate or 1% topical T gel.

Main Outcome Measure(s):

Luteinizing hormone, FSH, T, and semen analysis.

Result(s):

Treatment with enclomiphene citrate resulted in increased morning serum T, E2, and LH levels similar to those obtained with a topical T gel in men with secondary hypogonadism. Follicle-stimulating hormone and LH were increased with enclomiphene, and sperm counts were conserved.

Conclusion(s):

Enclomiphene citrate reverses the two hallmarks of secondary hypogonadism, namely, low serum total T and low or inappropriately normal LH while preserving sperm production.

Clinical Trial Registration Number:

NCT01270841 (ClinicalTrials.gov Identifier NCT01270841).

Read the full text at: http://www.fertstert.org/article/S0015-0282(14)00537-8/fulltext